Retatrutide + Cagrilintide

Composition

Retatrutide 20 mg, Cagrilintide 5 mg

Research overview

Retatrutide is an investigational multi-receptor agonist studied in metabolic research for interactions with GIP, GLP-1, and glucagon pathways. Published human studies and newer late-stage trial updates focus on body weight, glycemic markers, cardiometabolic endpoints, and tolerability.

Potential research areas

• ▸GIP / GLP-1 / glucagon signaling
• ▸Metabolic research models
• ▸Appetite and energy-balance pathways
• ▸Body-composition endpoints

Research profile

Retatrutide, identified in the literature as LY3437943, is an investigational peptide reported to act at three receptors: GIP, GLP-1 and glucagon. Phase 2 trials have reported body-weight and glycaemic endpoints. It holds no marketing authorisation from any regulator.